Hyloris Pharmaceuticals

Hyloris Pharmaceuticals has built a broad portfolio of value-added medicines by reformulating and repurposing existing pharmaceuticals. The company leverages the FDA’s streamlined regulatory pathway for established molecules to reduce development time and risk. As of early/mid–2025, it has two commercialized products—Sotalol IV for atrial fibrillation and Maxigesic® IV for post-operative pain—and over twenty additional programs at various stages of development targeting cardiovascular disease, pain management, iron deficiency, mineral disorders, and more.[1][5][6] The company aims to reach a pipeline breadth of around thirty assets by the end of calendar year 2025.[5]